SIMCERE PHARMA (02096.HK): SIM0709 trial cleared in Germany
- SIM0709 is a long-acting humanised bispecific antibody targeting TL1A and IL-23, blocking two core pathways in the onset and progression of IBD.
- Under the January 2026 licence, Boehringer Ingelheim holds ex-Greater China rights, with a EUR 42 million upfront payment and up to EUR 1.016 billion in milestones.
NewTimeSpace News: On 9 November 2026, Simcere Pharmaceutical Group Limited (Stock Code: 02096) said SIM0709, an in-house TL1A/IL-23p19 bispecific antibody, was cleared by Germany's Paul-Ehrlich-Institut and the competent ethics committee to start a phase I trial in healthy volunteers. SIM0709 is being developed globally with Boehringer Ingelheim for inflammatory bowel disease (IBD).
The announcement shows SIM0709 is a long-acting humanised bispecific antibody built on the company's multispecific platform targeting TL1A and IL-23, blocking two core IBD pathways to break the efficacy ceiling of single-target therapies; it showed superior synergy in vitro and in vivo, beating the two single agents combined. Under a January 2026 exclusive licence, Boehringer Ingelheim holds global rights outside Greater China, with Simcere receiving a EUR 42 million upfront payment, up to EUR 1.016 billion in milestones and tiered royalties on ex-Greater China net sales.
- SIMCERE PHARMA (02096.HK): zemprocitinib RA NDA accepted by NMPA
- SIMCERE PHARMA (02096.HK): Zemprocitinib dermatology rights secured
- SIMCERE PHARMA (02096.HK): RSV preventive biologic Yimule approved for marketing in China
- SIMCERE PHARMA(02096.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 828.72 million, YoY increase of 37.88%
- SIMCERE PHARMA (02096.HK): Zhu Da appointed Joint Company Secretary succeeding Wan Yushan, waiver granted from company secretary qualification requirements
